研究等業績 - その他 - 今井　一博

Trends in the evolution to robot-assisted minimally invasive thoracoscopic esophagectomy

Liu J.

Mini-invasive Surgery ( Mini-invasive Surgery )  4   2020年

DOI

Successful osimertinib rechallenge after osimertinib-induced interstitial lung disease in a patient with postoperative recurrence of lung cancer

Matsuo T.

Japanese Journal of Lung Cancer ( Japanese Journal of Lung Cancer )  59 ( 7 ) 1184 - 1189   2019年12月

<p><b>背景．</b>第3世代EGFRチロシンキナーゼ阻害薬であるオシメルチニブは，<i>EGFR</i>遺伝子変異陽性肺癌に対して高い奏効率，全生存期間の延長効果が示されているが，重篤な有害事象として薬剤性肺障害がある．<b>症例．</b>58歳，女性．検診で胸部異常陰影を指摘され，気管支鏡検査で<i>EGFR</i>遺伝子（exon19欠失）変異陽性肺腺癌と診断され，左上葉切除術＋2群リンパ節郭清を施行された．術後3年で多発肺転移が出現し，ゲフィチニブが開始された．3年間内服後に肺転移が増大し，経皮針生検でT790M耐性遺伝子が検出され，オシメルチニブを開始された．1年後に乾性咳嗽が出現し，右中葉にすりガラス影を認めた．薬剤性肺障害と判断し，オシメルチニブを中止し，プレドニゾロンの内服が開始された．陰影は軽快し，プレドニゾロンの内服を中止したが，肺転移が再増大したため殺細胞性抗癌剤が開始された．一時的に奏効したが，再増大したため，プレドニゾロン5 mg/日内服併用でのオシメルチニブの内服が再開された．薬剤性肺障害の再燃なく，現在も治療継続が可能である．<b>結論．</b>ステロイド内服併用で，オシメルチニブ内服再投与後も薬剤性肺障害の再燃なく治療継続が可能であった．</p>

DOI

Practical application of non-contact alternating current electric field mixing for reagent-saving in situ hybridisation of HER2

Kurihara N.

Journal of Clinical Pathology ( Journal of Clinical Pathology )  72 ( 9 ) 603 - 608   2019年09月

DOI

Phase II trial of induction chemotherapy with carboplatin and paclitaxel plus bevacizumab in patients with stage IIIA to IV nonsquamous non-small cell lung cancer

Imai K.

Surgery Today ( Surgery Today )  49 ( 8 ) 678 - 685   2019年08月

DOI

Extensive lymph node dissection around the left laryngeal nerve achieved with robot-assisted thoracoscopic esophagectomy

Motoyama S.

Anticancer Research ( Anticancer Research )  39 ( 3 ) 1337 - 1342   2019年03月

DOI

Reagent-saving immunohistochemistry for HER2 using non-contact alternating current electric field mixing

Hoshino I.

Journal of Clinical Pathology ( Journal of Clinical Pathology )  72 ( 1 ) 25 - 30   2019年01月

DOI

手術中に病気を視る迅速免疫染色入門

南條 博, 赤上 陽一, 中村 竜太, 廣嶋 優子, 寺田 かおり, 今井 一博, 南谷 佳弘

年次大会 ( 一般社団法人 日本機械学会 )  2019 ( 0 )   2019年

<p>Immunohistochemistry (IHC) is the most common application of immunostaining. It is widely used in the disgnosis of abnormal cells such as those found in cancerous tumors. Intraoperative pathological diagnosis is also important in selecting suitable surgery for cancer patients. We performed intraoperative diagnosis of 830 cases in Akita University Hospital., with a novel method of rapid-immunohistochemistory (R-IHC) using an alternating current electric field. The results were very good, R-IHC detected an objective evidence that were undetected using conventional HE staining. So we can diagnose degree of malignancy, histological type of cancer, and lymph node metastasis more accurately.</p>

DOI

肺癌のセンチネルノードナビゲーションサージェリーの現状

南谷 佳弘, 今井 一博, 今野 隼人, 栗原 伸泰, 中 麻衣子

日本気管食道科学会会報 ( 特定非営利活動法人 日本気管食道科学会 )  70 ( 2 ) 85 - 86   2019年

DOI

手術中に病気を視る迅速免疫染色入門

南條 博, 赤上 陽一, 中村 竜太, 廣嶋 優子, 寺田 かおり, 今井 一博, 南谷 佳弘

年次大会 ( 一般社団法人 日本機械学会 )  2019 ( 0 ) W02101   2019年

DOI CiNii Research

TLR3 expression status predicts prognosis in patients with advanced thoracic esophageal squamous cell carcinoma after esophagectomy

Sato Y.

American Journal of Surgery ( American Journal of Surgery )  216 ( 2 ) 319 - 325   2018年08月

DOI

Lung Cancer Surgery in Partial Anomalous Pulmonary Venous Connection Patients

Kurihara N.

Annals of Thoracic Surgery ( Annals of Thoracic Surgery )  105 ( 1 ) e7 - e9   2018年01月

DOI

電界非接触撹拌技術を応用した迅速免疫組織化学染色装置における液滴蒸散予防の工夫

星野 育, 佐藤 雄亮, 本山 悟, 南條 博, 赤上 陽一, 南谷 佳弘, 今井 一博, 中村 竜太, 斎藤 芳太郎, 藤嶋 悟志, 栗原 伸泰, 若松 由貴, 斎藤 元, 寺田 かおり

精密工学会誌 ( 公益社団法人 精密工学会 )  84 ( 4 ) 383 - 387   2018年

<p>It is widely recognized that pathology is the most important factor for staging and selecting effective chemotherapy for patients with cancer. Immunohistochemistry (IHC) is a reliable screening method, but intra-operative diagnosis by frozen section with IHC is not possible because IHC takes approximately 6 hours. We recently developed a rapid-IHC method that makes use of an alternating current (AC) electric field to facilitate the antigen-antibody reaction, and reported its usefulness for detection of lung cancer and breast cancer. The antibody is mixed within microdroplets as the voltage is switched on and off at specific intervals. The resultant Coulomb force stirs the diluted solution on the sections, which increases the opportunity for contact. The rapid-IHC device reduces the time required for IHC as well as the amount of antibody required for analyses. The device may also be applied for in situ hybridization (ISH); however, ISH requires a warm temperature, such as 37℃, and a longer processing time than the rapid-IHC method. Consequently, evaporation can be a problem during ISH. The aim of the present study was to evaluate the utility and reliability of an oil cover and cover cap made of polyethylene terephthalate (PET) for preventing evaporation due to the AC electric field applied to facilitate the antigen-antibody reaction. We have shown that both the oil cover and PET cover cap prevented evaporation when using the rapid-IHC device.</p>

DOI

Novel method for rapid fluorescence in-situ hybridization of ALK rearrangement using non-contact alternating current electric field mixing

Fujishima S.

Scientific Reports ( Scientific Reports )  7 ( 1 )   2017年12月

DOI

連載 行ってきました! 海外留学　(第38回) 米国デューク大学

今井 一博

胸部外科 ( 南江堂 )  70 ( 12 ) 1008 - 1009   2017年11月

DOI CiNii Research

Efficacy and safety of neoadjuvant chemoradiotherapy following esophagectomy with japanese-style extended 3-field lymphadenectomy for thoracic esophageal cancer

Motoyama S.

Anticancer Research ( Anticancer Research )  37 ( 10 ) 5837 - 5843   2017年10月

DOI

The low expression of MIR-451 predicts a worse prognosis in non-small cell lung cancer cases

Goto A.

PLoS ONE ( PLoS ONE )  12 ( 7 )   2017年07月

DOI

New PET/CT criterion for nodal staging in non-small cell lung cancer: measurement of the ratio of section area of standard uptake values ≥2.5/lymph node section area

Saito Y.

General Thoracic and Cardiovascular Surgery ( General Thoracic and Cardiovascular Surgery )  65 ( 6 ) 350 - 357   2017年06月

DOI

Pd-l1 expression is a prognostic factor in patients with thoracic esophageal cancer treated without adjuvant chemotherapy

Wakita A.

Anticancer Research ( Anticancer Research )  37 ( 3 ) 1433 - 1441   2017年03月

DOI